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Abstract
Objective: Diabetes mellitus is a growing public health problem, for which efficient and timely
surveillance is a key policy. Administrative databases offer relevant opportunities for this purpose.
We aim to monitor the incidence of diabetes and its major complications using administrative data.
Study design and methods: We study a population of about 850000 inhabitants in the Veneto
Region (Italy) from the end of year 2001 to the end of year 2004. We use four administrative
databases with record linkage. Databases of drug prescriptions and of exemptions from medical
charge were linked to identify diabetic subjects; hospital discharge records and mortality data were
used for the assessment of macrovascular and renal complications and vital status.
Results: We identified 30230 and 34620 diabetic subjects at the start and at the end of the study
respectively. The row prevalence increased from 38.3/1000 (95% CI 37.2 – 39.5) to 43.2/1000 (95%
CI 42.3 – 44) for males and from 34.7/1000 (95% CI 33.9 – 35.5) to 38.1/1000 (95% CI 37.4 – 39)
for females. The mean row incidence is 5.3/1000 (95% CI 5 – 5.6) person years for males and 4.8/
1000 (95% CI 4.4 – 5.2) person years for females. The rate of hospitalisations for cardiovascular or
kidney diseases is greatly increased in diabetic people with respect to non diabetics for both
genders. The mortality relative risk is particularly important in younger age classes: diabetic males
and females aged 45–64 years present relative risk for death of 1.7 (95% CI 1.58 – 1.88) and 2.6
(95% CI 2.29 – 2.97) respectively.
Conclusion: This study provides a feasible and efficient method to determine and monitor the
incidence and prevalence of diabetes and the occurrence of its complications along with indexes of
morbidity and mortality.
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Background
For an adequate health planning, policy-makers need con-
tinuous, accurate and timely data about the main diseases
affecting the population with a great impact on utilization
of health services. Diabetes mellitus represents an impor-
tant and growing problem in developed countries for its
prevalence and the high risk of major complications [1,2].
The burden of this disease is increasing worldwide both
for the progressive ageing of population and for the wors-
ening of life-style. This increase is expected both for type
2 and for type 1 diabetes [3,4].
A growing body of scientific literature is now available on
the use of administrative data for surveillance purposes.
Surveillance with administrative data is feasible, timely,
little expensive and involves, with a wide coverage and
continuity, a high number of subjects. For these feature,
administrative databases are widely used for epidemio-
logic purposes and health services research.
Diabetic disease is an ideal model for surveillance with
administrative data. First, monitoring diabetes and its
complications is a key policy in public health surveillance
for defining the burden of disease, for planning health
services, for evaluating strategies in disease prevention
and control and assessing outcomes. Second, diabetes
presents a feasible detection and follow-up by the use of
current data, i.e, a highly specific pharmacologic treat-
ment, high rate of hospitalisation and, at least in Italy,
dedicated diabetes care units when the disease is certified;
moreover, since that diabetic subjects have some facilities
for out of hospital care, local health authorities keep a reg-
ister of subjects with a diagnosis of diabetes (as well as
other chronic diseases) for administrative purposes. Vari-
ous approaches have been proposed to assess the burden
of diabetes and its consequences with administrative data
[5-10], and their validity has been widely demonstrated
[11,12] and recently reviewed [13]. However, the rare
opportunity given by the Italian health system of two dif-
ferent administrative databases with a high traceability of
diabetic subjects has not been sufficiently explored; fur-
thermore the studies about the epidemiology of diabetes
and its complications with administrative data are limited
to particular aspects (incidence or prevalence or complica-
tions or quality of care), without a global picture of the
diabetic disease.
Therefore the aim of this study was to propose a model for
the surveillance of diabetes and its complications with the
use of four different archives of administrative data (hos-
pital discharge records, mortality data, drug prescriptions
and exemption from medical charge) with record-linkage
between the four databases. Specifically we wish to deter-
mine the prevalence and the incidence of diabetes and the
detection of its major complications (cardiovascular and
renal) and mortality in diabetic patients.
Methods
This is a retrospective cohort study, based on administra-
tive data from 2001 to 2004.
We consider data from three local Health authorities in
the Veneto Region (North-East Italy). The total popula-
tion observed is about 850000 people (20% of the
regional population).
Data sources
We used hospital discharge records (HDRs, years 2002–
2004), mortality data (MD, years 2002–2003), drug pre-
scriptions (DP, years 2001–2004) and exemption of med-
ical charge (EMC, years 2001–2004). We provide a brief
description of the four databases, with more details about
EMC, a peculiarity of the Italian Health System.
Hospital discharge records
HDRs contain personal data (first name, last name, date
and place of birth, residence, fiscal identification number
and health service identification number) and hospitali-
sation data (date and ward of admission, date and ward of
discharge, date and ward of transfers, if any). There are
one principal discharge diagnosis and up to five other sec-
ondary diagnosis; there are up to six medical or surgical
procedures. Since year 2000, diagnosis and procedures are
codified according to ICD-9-CM codes (1997 version).
Mortality data
Each local health Authority must keep and maintain a reg-
ister of mortality data. The MD records contain personal
data (first name, last name, date and place of birth, resi-
dence and fiscal number) and a unique cause of death,
codified with ICD-9 codes (according to rules of national
institute of statistics, adapted from World Health Organi-
sation indications).
Drug prescriptions
Archives of drug prescriptions are collected by local health
authorities and contain data about the patient, about the
prescribing physician and about the drugs. Drugs are clas-
sified according the Anatomical Therapeutic Chemical
(ATC) classification system. We extract the records with
the following ACT codes :A10A (insulin) and A10B (oral
antidiabetic drugs).
Exemption from medical charge
In the Veneto Region, public hospital care is free of charge.
Subjects aged under 65 years must pay a part of out-of-
hospital care (laboratory tests, specialistic visits,...) and
must contribute to drug costs. If a subject is certified as
diabetic, all the out-of-hospital care concerning diabetes isCardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
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free of charge. This comprises laboratory controls
(HbA1C, lipids, microalbuminuria...) periodical clinical
evaluations (diabetologist, ophthalmologist...), instru-
mental examinations (ECG, ecocolordoppler...,), self-
monitoring glucose strips and antidiabetic drugs (and
needles for insulin, when needed). Thus, the local health
authorities keep a register of the subjects certified as dia-
betics. In a recent survey in the Veneto Region we estab-
lished that the positive predictive value of EMC for the
diagnosis of diabetes is 98% in a sample of people aged
18–65 years (unpublished data).
Record-linkage
The four databases employed different personal identifi-
cation data; therefore, we consider as valid only those
records that match with the regional archive of people
covered by health assistance (i.e., all people who is regu-
larly resident in the Veneto Region). Even if with different
identification data, HDRs, mortality data and EMCs are all
connected through the archive of people covered by
health assistance; linkage of these archives therefore
approximates 100%. Drug prescriptions are linked with
the archive of people covered by health assistance by a
personal identification code: about 5% of single drug pre-
scriptions did not link. Since that diabetic people usually
have more than one prescription the probability that a
diabetic subject with multiple drug prescriptions is missed
by our system is quite low.
People coming from developing countries presents some
problems in the linkage, because of the inaccuracy or the
lack of personal data. Since that in the Veneto Region they
account for 5% of the total population and since that their
age is young, we are confident that the potential under
detection of diabetics is of little extent.
Prevalence and incidence
Prevalent cases are defined at the end of each year. For
example, we compute prevalence of diabetes at the end of
year 2001 considering in the numerator all subject with
one or more prescriptions of antidiabetic drugs in the last
six months of the years 2001 and/or subjects present in
the EMC at the end of 2001. For subjects present only in
DP database two or more prescriptions of antidiabetic
drugs are required for the labelling as diabetic people.
Women aged 15–44 years (reproductive age) with only
one prescription of insulin or traceable in the EMC data-
base only temporarily, were excluded to avoid the inclu-
sion of gestational diabetes.
Incident cases of diabetes are identified each year by sub-
tracting from diabetic subjects at the end of the year those
already identified at the end of the previous year: subjects
defined as diabetic at the end of the years 2002 but not
present in the PD or EMC databases at the end of 2001
were considered incident cases in the year 2002.
Data are presented at the start and at the end of the study
period as row and standardized prevalence and incidence
rates as well as age and gender specific prevalence and
incidence rates.
Hospitalised complications and mortality
For the entire period of the study, we calculated the hos-
pitalisation rates among diabetics and non diabetics,
through the record linkage of the previously identified
diabetic population with the database of HDRs.
We assess the hospitalisation for the following nine
causes: all causes, ischemic heart disease, acute myocar-
dial infarction, heart failure, stroke, all cerebrovascular
diseases (comprising stroke), peripheral vascular diseases,
low limb amputations, renal diseases. In table 1 are listed
the ICD-9-CM codes utilised for the identification of these
conditions.
Table 1: ICD-9-CM codes for the identification of complications in Hospital Discharge Records
Condition ICD-9-CM codes Fields
Ischemic heart disease 410xx, 411xx, 412, 413x, 414xx Primary diagnosis
Acute myocardial infarction 410x1 All diagnostic fields
Heart failure 428x, 7855x Primary diagnosis
Cerebrovascular diseases 430, 431, 432x, 433xx, 434xx, 435, 436, 437x, 438 Primary diagnosis
3811, 3812, 3831, 3832, 3841, 3842 All procedural fields
Stroke 430, 431, 433x1, 434x1, 436 Primary diagnosis
Peripheral vascular disease 2507x, 440xx, 442xx, 443xx, 444xx, 447x, 459xx, 7854 Primary diagnosis
V434, 3813, 3814, 3815, 3816, 3818, 3925, 3929 All procedural fields
Low limb amputations 895x, 896x, 897x All diagnostic fields
8410, 8411, 8412, 8413, 8414, 8415, 8416, 8417, 8418, 8419, 8622 All procedural fields
Kidney diseases 2504x, 403xx, 404xx, 581xx, 584x, 585, 586, 588x Primary diagnosis
3895, 3927, 3942, 3995, 5493 All procedural fieldsCardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
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For each class of age and gender we report the rate of hos-
pitalisation for each cause in diabetics and the relative risk
with respect to non diabetic people.
The record-linkage between the diabetic population and
the archive of mortality data (years 2002–2003) allows to
compute mortality rates in diabetics and non diabetics.
Because of the known low accuracy of the causes of death
in death certificates, and the lack of multiple causes and
concomitant diseases in our database, we did not use
death certificates for the analysis of the causes of death.
Even mortality data are presented as gender and age spe-
cific rates and relative risk.
Statistical analysis
For row age and gender specific prevalence and incidence
rates, 95% confidence intervals are determined with the
approximation to the normal distribution, for relative
risks for hospitalisation and mortality we assumed a log-
normal distribution. Standard errors are computed with
the usual methods[14].
The standardization for prevalence and incidence rates
was performed with the direct method, using age and gen-
der specific rates for the following classes of age: 0–4, 5–
14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84,
85 and over. The standard population is the Italian popu-
lation of the year 2000, source national institute of statis-
tic)
Record linkage and analysis was performed with the statis-
tical software package SAS vers 9.
Results
Occurrence of diabetes
The diabetic subjects identified at the start and at the end
of the study are 30230 and 34620 respectively. There is a
slight prevalence of male gender (52%). Of importance,
diabetic subjects are identified by the presence in the EMC
database only in 16% of cases, by the presence in the DP
database in the 24% of cases, and by the presence in both
databases in 60% of cases. The proportion of diabetic
patients treated only with oral antidiabetic drugs is 65%,
while 19% of patients assumes either insulin only (60%)
or in combination with oral antidiabetic drugs (40%).
The row prevalence for males is 38.3/1000 in the begin-
ning and 43.2/1000 at the end of the study ; for females
34.7/1000 and 38.1/1000, respectively (p < 0.001). The
standardised prevalence rates in the beginning and at the
end of the study are 39/1000 and 43.5/1000 for males,
34.7/1000 and 37.6/1000 for females, respectively (p <
0.001). Row and standardised prevalence rates both
increase by about 10% through the three years studied.
The row incidence rate of diabetes for the period 2002 –
2004 is 5.3/1000 person years for males and 4.8/1000
person years for females. The standardized incidence rate
of diabetes for the same period is 5.5/1000 person years
for males and 5/1000 person years for females.
The age and sex specific prevalence and incidence rates are
shown in table 2 and in figures 1 and 2.
Major complications and mortality
Diabetic patients show increased rates of hospitalisation
for all causes and for cardiovascular and renal causes
(table 3 and figures 3, 4, 5 and 6) as compared to non-dia-
betic subjects. The effect of diabetes in terms of relative
risk is present in each group of age and for each cause,
except for cerebrovascular diseases, stroke and kidney dis-
eases for elderly males. Absolute rates are higher specifi-
cally in older males; on the contrary, relative risk is higher
distinctively in younger women. For younger classes of
age and for certain causes (heart failure, peripheral vascu-
lar diseases, kidney diseases) the risk of hospitalisation
among diabetic subjects is even five-fold or more respect
to non diabetic people.
The relative risk of mortality in diabetic subjects aged 45–
64 years is increased both for males and females (1.7 and
2.6 respectively), while there is no difference in the risk of
death between diabetics and non diabetics in subjects
older than 74 years.
Discussion
This study provides a useful model to identify diabetic
subjects, to describe the burden of the disease in terms of
diabetic complications, health services utilisation, and
health outcome. The combined use of drug prescription
and of exemption from medical charges to identify dia-
betic patients allows a significant increase of sensitivity,
maintaining a high specificity, with respect to use of drug
prescription only. In effect, with the DP, diabetic subjects
that not assume antidiabetic drugs cannot be traced, while
they could be present in the archive of EMC. In our study
16% of the total diabetic population is detected by the
presence in the EMC database only.
A questionable issue is the accuracy of the EMC database
in the identification of diabetic people. We reported
above in the paper a very high positive predictive value of
this database for the identification of diabetic subjects.
The sensitivity, however, may be suboptimal: Gnavi et al
[15] reported that 73% of subjects assuming antidiabetic
drugs are traceable in the database of exemption from
medical charge, an amount similar to our findings (71%).
Nevertheless, diabetic subjects not present in the EMC
database can be traced with DP, so we are confident thatCardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
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the accuracy of the combined use of the two databases is
characterised by high sensitivity and specificity.
The estimates of prevalence, incidence and time trends are
consistent with other national [16,17] and international
surveys [18,19], conducted with other more accurate but
expensive methodologies. Bonora et al [16] reported an
incidence rate of 9.1 and 11.9 for 1000 person-years in
people aged 50–59 and 60–69 years respectively, with no
difference between gender. Bruno et al reported incidence
rates of 1.5 and 0.76 for 1000 person-years respectively in
men and women aged 45–49 years. We found incidence
rates of 6.7 and 3.5 respectively for males and females
aged 45–54 years and incidence rates of 12.8 and 7.6 for
1000 person-years respectively for males and females aged
55–64 years.
Fleming et al [18] reported a prevalence of diabetes in
eight European countries for people aged 45–64 years
ranging from 33.3 to 58.1 per 1000 and from 21 to 53 per
Prevalence (*1000 subjects) of diabetes in males Figure 1











Under 45 years 45-54 years 55-64 years 65-74 years 75-84 years Over 84 years Overall
standardized
Table 2: Age and gender specific occurrences of diabetes.
Prevalence (*1000 subjects) Incidence (*1000 person years)
31/12/2001 31/12/2004 Mean 2002 – 2004
males females males females males females
Under 45 years 5.6 4.2 5.5 5 1.3 1.1
5.3–5.9 4–4.5 5.2–5.8 4.7–5.3 1.2–1.4 1–1.2
45–54 years 40.1 21 41.2 19.4 6.7 3.5
39–42 19–23 40–43 18–21 6.3–7.2 3.2–3.8
55–64 years 91.2 55 99.9 56.6 12.8 7.6
89–95 53–57 97–102 55–59 12.2–13.5 7.1–8.1
65–74 years 132 96.4 152 102.9 17 12.4
129–136 94–100 148–156 100–106 16.1–18 11.7–13.1
75–84 years 134 125 162.1 141.4 15.9 15.5
129–140 121–129 157–167 138–145 14.7–17.1 14.6–16.4
Over 84 years 105 122 139.3 141.6 16.2 15.5
97–114 116–128 129–150 135–148 13.8–18.9 14–17
Overall standardized 39 34.7 43.5 37.6 5.5 5.0
37-41 33-36 42-45 36-40 (5.2-5.8) (4.7-5.3)Cardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
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1000 in males and females respectively. We found at the
start of our study a prevalence of 40.1 per 1000 in men
aged 45–54 years, 91.2 per 1000 in men aged 55–64 years,
21 per 1000 in women aged 45–54 years and 55 per 1000
in women aged 55–64 years.
The results about hospitalisation for all causes and for car-
diovascular and renal diseases is consistent with the
expected burden of major complications in diabetic peo-
ple and with previous reports [22]. For example, Bo et al
in a recent paper [10] reported standardised hospital
admission ratios for heart diseases in diabetic subjects
aged 30–64 years of 230% for males and 341% for
females: even if not directly comparable for several rea-
sons (different classes of age, different aggregations of
clinical conditions, different measures of association) our
findings about this issue are very similar in a qualitative
and a quantitative point of view (relative risk of hospital-
isation for acute myocardial infarction in diabetic subjects
aged 45–64 years of 3.2 and 6.2 for males and females
respectively). An important and relatively novel finding of
this study is that diabetes has a great impact on occurrence
of cardiovascular diseases in people with otherwise low
risk, and confirm the disease partially abolish the differ-
ence in the burden of cardiovascular diseases between
genders: the DAI study assessed the prevalence of cardio-
vascular complications in diabetic subjects and showed
that diabetic females present a prevalence of cardiovascu-
lar complication as high as diabetic males or even higher
[20]. Donnan et al [21] report a relative risk of hospitali-
zation for many causes in diabetic subjects respect to non
diabetic people as a single estimate adjusted for age and
sex. We prefer show age and sex specific estimates because
in this manner we can describe the particularly great
impact of diabetes in younger subjects and in females.
The relationship between diabetes and mortality identi-
fies some features common to hospitalisation: absolute
risk greater in males and older people and relative risk
greater in females and younger subjects. In elderly dia-
betic subjects the mortality rates were similar to non dia-
betic subjects, with relative risk similar between genders:
this means that the effect of diabetes on mortality tends to
faint when age increases. The association between diabe-
tes and mortality, that substantially disappear with the
increase of age, is coherent with other studies [7].
Although in this study we limit our analysis to few items,
other aspects should be investigated with a similar
approach such as the follow-up of a cohort of incident
cases with the evaluation of the evolution in antidiabetic
treatment, the prevalence of other cardiovascular risk fac-
tors assessed by pharmacological treatment.
The present study has some limitations. We can trace only
subjects with known diabetes: i.e. subjects who are utiliz-
ing health services. Moreover, subjects with known diabe-
tes could escape to identification with current data if he/
she doesn't assumes antidiabetic drugs nor requires the
certificate for exemption from medical charges (for exam-
Prevalence (*1000 subjects) of diabetes in females Figure 2
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ple all subjects aged 65 years or more are free from the
great part of the out-of-hospital medical assistance). How-
ever, these limitations should not underestimate the
occurrence of diabetes to a significant extent because dia-
betic subjects who did not assume antidiabetic drugs and
not traceable in the EMC database are a little part of the
diabetic population.
Another limit of this study is the lack of validation. How-
ever, we believe that this is a minor limitation since the
high sensitivity of antidiabetic drugs in identifying dia-
betic people has been established by several studies in dif-
ferent settings. Because of the undercoding of diabetes in
hospital discharge records, we assessed the hospitalisa-
tions of diabetic patients with record-linkage between the
HDRs archive and the diabetic population otherwise iden-
tified. We defined the causes of hospitalisation by prefer-
entially using codes with established accuracy (acute
myocardial infarction [23], stroke [24]), or, otherwise
widely used in scientific literature or by public agencies
[25]. Because of the low accuracy of the diagnosis of dia-
betes in death certificates we refer to these only for the
assessment of the death. Our data are consistent with
other published studies on the same epidemiological
aspects carried out with other more accurate but more
expensive methodologies.
We did not distinguish between type 1 and type 2 diabetes
mellitus: we did so because with current data a clear dis-
tinction is not possible. We can classify diabetic subjects
according to treatment or to age of diagnosis; unfortu-
nately, we lack data on the presence of ICA or GADA auto-
antibodies or data about the levels of C-peptide. We are
aware that the excess of cardiovascular and renal compli-
cations in diabetic subjects is due not only to diabetes but
even (mainly) to other risk factors: hypertension, dyslipi-
demia, obesity (the metabolic syndrome); however we
outline two important elements: first, hyperglycaemia per
se even under the diabetic range may lead to the develop-
ment of cardiac diseases [26]; second, the approach to the
diabetic patients must consider these subjects as a whole,
with careful attention to the control of all cardiovascular
Table 3: Hospitalisation* and mortality in diabetic subjects, by age and gender.
45–64 years 65–74 years Over 74 years
males females males females males females
All hospitalisations Rates 376 363 569 417 668 527
RR 2.04 2.04 1.33 1.47 1.07 1.19
95% ci 1.99–2.08 1.99–2.1 1.31–1.35 1.43–1.50 1.05–1.08 1.17–1.21
Ischemic heart disease Rates 29.3 11.1 36.8 22.4 37.4 27.9
RR 3.37 7.36 1.72 3.26 1.18 1.72
95% ci 3.06–3.7 5.98–9.04 1.56–1.90 2.83–3.75 1.05–1.32 1.55–1.91
Acute myocardial infarction Rates 8.1 3 8.9 5.1 13 11.1
RR 3.22 6.21 1.76 2.58 1.23 1.74
95% ci 2.69–3.85 4.2–9.19 1.43–2.17 1.94–3.45 1.01–1.5 1.48–2.06
Heart failure Rates 9.2 4.1 21.9 13 39.3 34.7
RR 6.14 9.28 2.55 3.15 1.23 1.42
95% ci 5.11–7.36 6.52–13.19 2.22–2.93 2.62–3.79 1.09–1.38 1.29–1.55
Cerebrovascular diseases Rates 13.2 9.2 32.6 19.1 37.3 35.4
RR 3.64 4.61 2.03 2.34 0.95 1.28
95% ci 3.16–4.19 3.71–5.72 1.82–2.26 2.02–2.71 0.58–1.06 1.17–1.40
Stroke Rates 6.2 4.2 12.5 7.3 15.3 16.5
RR 3.64 4.81 1.88 2.28 0.88 1.20
95% ci 2.96–4.48 3.48–6.66 1.58–2.25 1.79–2.89 0.74–1.06 1.05–1.37
Peripheral vascular diseases Rates 20.2 8.7 34.6 8.8 35.7 14.9
RR 7.25 10.48 2.49 2.84 1.7 2.17
95% ci 6.4–8.22 8.21–13.37 2.24–2.78 2.27–3.55 1.5–1.92 1.87–2.51
Low limb amputations Rates 6.7 2.8 6.2 1.7 6 4.7
RR 13.01 10.27 6.1 2.85 2.38 3.04
95% ci 10.16–16.66 6.68–15.78 4.47–8.31 1.72–4.7 1.73–3.27 2.31–3.99
Kidney diseases Rates 11.3 8.5 13.6 7.8 10.7 8
RR 6.04 6.21 2.75 2.8 0.97 1.88
95% ci 5.13–7.12 4.93–7.83 2.31–3.29 2.21–3.54 0.78–1.21 1.54–2.28
Mortality Rates 9.23 6.93 26.4 16.1 83.6 63.4
RR 1.72 2.62 1.1 1.86 0.98 1.02
95% ci 1.58–1.88 2.29–2.97 1.02–1.21 1.74–1.98 0.91–1.06 0.94–1.11
* Rates (*1000) in diabetics and relative risk with 95% confidence interval (respect to non diabetics)Cardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
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Relative Risk of hospitalisation for acute myocardial infarction Figure 3

























Relative Risk of hospitalisation for Stroke Figure 4
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Relative Risk of hospitalisation for peripheral vascular diseases Figure 5























Relative Risk of hospitalisation for kidney diseases Figure 6























MALES FEMALESCardiovascular Diabetology 2007, 6:5 http://www.cardiab.com/content/6/1/5
Page 10 of 11
(page number not for citation purposes)
risk factor (in this light we can see diabetes as an indicator
of high cardiovascular risk).
Conclusion
The main strength of this study is the ability to give con-
siderable informations about the prevalence and inci-
dence of diabetes and its complications in a manner
suitable to policy-makers for health planning: sufficient
accuracy, timely availability, low cost and high sustaina-
bility. Another important aspect is the finding that diabe-
tes has a major effect for the risk of cardiovascular diseases
in people otherwise at low risk.
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